JP2005528337A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528337A5
JP2005528337A5 JP2003558463A JP2003558463A JP2005528337A5 JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5 JP 2003558463 A JP2003558463 A JP 2003558463A JP 2003558463 A JP2003558463 A JP 2003558463A JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5
Authority
JP
Japan
Prior art keywords
xaa
gly
ser
glp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003558463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528337A (ja
JP4282485B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/000001 external-priority patent/WO2003058203A2/en
Publication of JP2005528337A publication Critical patent/JP2005528337A/ja
Publication of JP2005528337A5 publication Critical patent/JP2005528337A5/ja
Application granted granted Critical
Publication of JP4282485B2 publication Critical patent/JP4282485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003558463A 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ Expired - Fee Related JP4282485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34647402P 2002-01-08 2002-01-08
US40509702P 2002-08-21 2002-08-21
PCT/US2003/000001 WO2003058203A2 (en) 2002-01-08 2003-01-03 Extended glucagon-like peptide-1 analogs

Publications (3)

Publication Number Publication Date
JP2005528337A JP2005528337A (ja) 2005-09-22
JP2005528337A5 true JP2005528337A5 (enExample) 2006-02-02
JP4282485B2 JP4282485B2 (ja) 2009-06-24

Family

ID=26994870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558463A Expired - Fee Related JP4282485B2 (ja) 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ

Country Status (11)

Country Link
US (1) US7482321B2 (enExample)
EP (1) EP1585959A4 (enExample)
JP (1) JP4282485B2 (enExample)
AR (1) AR038102A1 (enExample)
AU (1) AU2003200839B2 (enExample)
BR (1) BR0306706A (enExample)
CA (1) CA2468700A1 (enExample)
MX (1) MXPA04006679A (enExample)
PE (1) PE20030820A1 (enExample)
TW (1) TW200306202A (enExample)
WO (1) WO2003058203A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
EP1694356B1 (en) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
BRPI0506694A (pt) 2004-01-08 2007-05-02 Theratechnologies Inc análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
JP2008501765A (ja) * 2004-06-11 2008-01-24 ノボ ノルディスク アクティーゼルスカブ Glp−1アゴニストを用いた薬剤誘発性肥満の中和
CA2577326A1 (en) * 2004-08-18 2006-03-02 Eli Lilly & Company Selective vpac2 receptor peptide agonists
EP1845105A4 (en) 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical MODIFIED EXENDINES AND CORRESPONDING USES
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
MX2007013655A (es) * 2005-05-05 2008-01-24 Cadila Healthcare Ltd Nuevos compuestos como agonistas glp-i.
KR101011081B1 (ko) * 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Peg화된 glp-1 화합물
EP1915393A1 (en) * 2005-08-11 2008-04-30 Eli Lilly And Company Selective vpac2 receptor peptide agonists
PT1767545E (pt) 2005-09-22 2010-02-05 Biocompatibles Uk Ltd Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
AU2006306236B2 (en) 2005-10-26 2011-12-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
JP2009514900A (ja) * 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Glp−1のポリマ複合体
US20100048460A1 (en) * 2006-02-28 2010-02-25 Lianshan Zhang Selective vpac2 receptor peptide agonists
JP2009532422A (ja) * 2006-04-03 2009-09-10 ノボ・ノルデイスク・エー/エス Glp−1ペプチドアゴニスト
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴン/glp−1受容体コアゴニスト
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
JP2010535781A (ja) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
CA2812102A1 (en) 2010-11-24 2012-06-07 Durect Corporation Biodegradable drug delivery composition
CA2821766A1 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
EA031230B1 (ru) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты глюкагонового рецептора/glp-1-рецептора
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
EP2729157B1 (en) * 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
TW201334791A (zh) 2011-11-23 2013-09-01 杜瑞克公司 輻射滅菌之可生物降解之藥物遞送組合物
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
EP3010546B1 (en) * 2013-06-20 2017-08-09 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
ES2980707T3 (es) 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ N末端修飾glp−1誘導体
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
UA93662C2 (uk) * 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
CA2455963C (en) * 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
JP2005508360A (ja) * 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Glp−1およびインスリンの二相混合物

Similar Documents

Publication Publication Date Title
JP2005528337A5 (enExample)
JP2010538049A5 (enExample)
US10961287B2 (en) Extended recombinant polypeptides and compositions comprising same
JP2008533105A5 (enExample)
EP3398961B1 (en) Triple activator activating glucagon, glp-1 and gip receptor
JP2014529629A5 (enExample)
RU2006120079A (ru) Производные глюкагоноподобного пептида-1 (glp-1)
JP2001011095A5 (enExample)
RU2007119990A (ru) Слитые конструкции лекарственного средства и конъюгаты
EP2729481B1 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2013517307A5 (enExample)
RU2007134156A (ru) Ацилированные glp-1 соединения
JP2013543853A5 (enExample)
EP2844269A1 (en) Transmucosal delivery of engineered polypeptides
JP2004509079A5 (enExample)
TW201010729A (en) GIP-based mixed agonists for treatment of metabolic disorders and obesity
JP2002538081A (ja) Glp−1の類似体
JP2005528337A (ja) 伸長グルカゴン様ペプチド−1アナログ
JP2007519642A5 (enExample)
JP2005514060A5 (enExample)
TW200848423A (en) Glucagon/GLP-1 receptor co-agonists
WO2011020320A1 (zh) 促胰岛素分泌肽类似物同源二聚体及其制备方法与用途
PE20231842A1 (es) Coagonistas de los receptores de glp-1 y gip
JP2014501712A5 (enExample)
AU2003200839A2 (en) Extended glucagon-like peptide-1 analogs